Erasca, Inc. is a clinical stage precision oncology company dedicated to discovering developing and commercializing therapies for patients with RAS MAPK pathway driven cancers. The company focuses on the RAS gene and its downstream signaling cascade which are among the most frequently altered molecular drivers in human malignancies. Erasca was co founded by leaders in precision oncology and RAS targeting to build a pipeline that aims to shut down the pathway through multiple complementary approaches. Its modality agnostic strategy allows the use of small molecule therapeutics large molecule antibodies or other formats as best suited to each target. The firm currently advances two clinical stage programs ERAS 0015 a pan RAS molecular glue and ERAS 4001 a pan KRAS inhibitor together with an earlier stage EGFR D2 D3 biparatopic antibody candidate ERAS 12. By targeting upstream downstream nodes RAS directly and emergent escape routes Erasca seeks to provide robust inhibition of oncogenic signaling and prolong survival in patient populations with high unmet medical need. Its research efforts are supported by a team of experienced drug discoverers developers and company builders who share a commitment to translating scientific insights into potential medicines.

Erasca generates revenue primarily from licensing agreements milestone payments and potential future product sales. The company has entered into exclusive worldwide licenses with third party owners of intellectual property such as Guangzhou Joyo Pharmatech for ERAS 0015 and Medshine Discovery for ERAS 4001 receiving upfront cash payments and committing to pay development regulatory and commercial milestones plus low to mid single digit royalties on net sales. In addition Erasca acquired EGFR antibody assets from Emerge Life Sciences through an asset purchase agreement that involved an upfront payment and issuance of shares. While the firm has not yet commercialized any therapeutic product it anticipates future revenue from the sale of approved drugs targeting RAS MAPK alterations. Collaborative arrangements such as the clinical trial supply agreement with Tango Therapeutics also provide potential revenue streams through cost sharing and co development incentives. The company also expects to receive funding from government and non profit organizations that support early stage oncology research although such inflows are not a core component of its revenue model. Until a product receives marketing approval the company relies on these partnership based inflows to fund its research and development activities.

Erasca occupies a niche within the broader oncology sector as a specialist in RAS MAPK pathway targeted therapeutics. The field includes large established players such as Amgen Roche Genentech and Bristol Myers Squibb that have approved inhibitors against individual nodes like KRAS G12C MEK and EGFR. Erasca differentiates itself through a modality agnostic pipeline that seeks to simultaneously hit multiple nodes and cooperative mechanisms reducing the likelihood of resistance. Its scientific advisory board comprises world renowned experts in RAS signaling including pioneers from academic institutions and industry who guide target selection and experimental design. The company’s intellectual property portfolio consists of dozens of pending and issued patents covering its molecular glue small molecule and antibody programs providing a foundation for exclusivity. By focusing exclusively on the RAS MAPK cascade Erasca aims to address more than five million new patients diagnosed each year with alterations in this pathway many of whom lack effective treatment options. While many competitors focus on single agent inhibition of a specific mutation Erasca’s approach combines multiple modalities to attack the pathway from several angles which may improve durability of response.

Erasca serves patients with RAS MAPK driven solid tumors who are enrolled in its clinical trials or who may receive its future approved therapies. The company works with hospitals cancer centers and research institutions that host its Phase 1 studies such as AURORAS 1 BOREALIS 1 and the China based JYP0015M101 trial. Licensing partners including Joyo Medshine and ELS act as collaborators providing early stage assets and sharing development costs. Erasca also engages with contract research organizations clinical trial sites and data management firms to support its study execution and regulatory submissions. Although no product is currently sold commercially the firm anticipates that its eventual customers will include oncologists hospitals health systems and payers in the United States Europe and other regions where it seeks regulatory approval. The company also interacts with patient advocacy organizations that provide insights into unmet needs and help shape clinical trial design.